Pharmaceutical Technology E-Alert:
Having trouble viewing this e-mail? Click here.
  Pharmaceutical Technology Europe E-Alert
 
21 September 2012

IN THIS ISSUE
Pharmacovigilance fees
Innovation at J&J
Bayer and Teva
Alzheimer's research

 
European Pharmacovigilance Fees Criticised
The European Generic Medicines Association (EGA) has raised concerns about the potential fees that may be charged by the European Medicines Agency for pharmacovigilance activities. More...
 
J&J to Establish Innovation Centres
Johnson & Johnson has announced plans to open four innovation centres in California, Boston, London and China, with the aim of accelerating early innovation and facilitating collaboration and investment opportunities. More...
 
Bayer HealthCare Acquires Teva's US Animal Health Business
Bayer HealthCare and Teva Pharmaceutical Industries have announced an agreement whereby Bayer will acquire the US-based animal health business of Teva for up to $145 million. More...
 
PhRMA Awards Ceremony Inspiring for Alzheimer's Workers, Researchers
The Pharmaceutical Research and Manufacturers of America (PhRMA) recently honoured nine individuals for their research into and fight against Alzheimer’s Disease (AD) as part of the association’s new Research and Hope Awards. More...
 
Join our community on LinkedIn
Want to discuss any of this week's news stories or any other hot topics in the industry? Then why not join our group on LinkedIn? More...
Key Topics:

Latest blog posts
Odorous Taints Linked to Treated Wood Pallets
GDUFA's Effect on Drug Master Files
MIT Survey aims to Correlate Product Lifecycle and Manufacturing Site Characteristics with Product Deviations
More blog posts

Latest articles
Regulatory Intervention in Paediatric Medicines
Tackling Tablet Sticking
Pre-use Filter-Integrity Testing: To Test or Not To Test?
More articles

Upcoming events
CPhI Worldwide (9–11 October | Spain)
ICH Q 9 Training Course (24–25 October | Austria)
European Pharmaceutical Pricing & Reimbursement (29–30 October | UK)
More events

Products/Service Profiles
Agilent

Realize Effective Pharmaceuticals
Reliable solutions enable pharmaceutical scientists to innovate in disease research, accelerate drug discovery and have greater confidence throughout development and manufacturing. Agilent solutions in genomics research, automation, separation and detection technologies along with workflow driven software solutions helps deliver the answers to bring effective therapeutics to market.
Learn more at www.agilent.com/lifesciences/realizepharma

 
Agilent

Agilent ICP-MS/ICP-OES
Reliable solutions for regulated pharmaceutical laboratories

Complying with new elemental impurity limits as defined by draft USP methods <232>/<233> could pose a significant challenge. You need to choose qualified hardware and software, ensure verification, and maintain electronic records. But there is a simple answer – Request a free copy of our primer on Elemental Impurity Analysis to learn more

 
BASF SE, G-ENP/K

The PeroXealTM packaging concept protects BASF’s Kollidon® products from atmospheric oxygen, increasing stability and ensuring consistent performance. This opens the door for entirely new applications – in particular for oxygen-sensitive APIs. Read more

 
Celanese

Learn more about VitalDose® EVA excipients on the VitalDose blog
Learn how EVA polymers have been used for years in controlled release pharmaceutical and medical device applications. Read more

 
Intertek

Pharma and Biopharma Outsourcing Solutions from Intertek
Intertek‘s expert pharmaceutical analysis, auditing and regulatory services are helping clients to save costs. Successful innovative, tailored programmes for biologics and pharmaceuticals can be applied to product / clinical development and manufacturing. ICSE, Stand 10E89. Read more


Event Profile
Perkin Elmer

3 Live Webinars coming soon.
Supply chain security - how best to use the most important tool in supply chain protection
Infrared spectroscopy is the most economical way to screen against many of the risks that exist today in your supply chain of raw materials – counterfeit, contaminated, adulterated, diluted, substituted, false claims of purity/source etc.
Read more

 
Survey
What do you think will be the greatest benefit of FDA's Generic Drug User Fees Amendments of 2012 (GDUFA)?
 
It will accelerate application review times 53%
 
 
It will increase the number of foreign inspections 26%
     
 
It will increase the transparency of manufacturing sites 21%

This week we would like to know...

The European Generic Medicines Agency has recently claimed that the potential fees to be charged by the European Medicines Agency for pharmacovigilance activities are unjustifiably high. Do you agree?

Click here to vote

Contact Us
Click here to contact editorial.

Click here to contact sales.